Role of Sorcin and Annexin A3 in Breast Cancer Patients

NCT03598660 | Unknown

• 1 other identifier: Breast cancer
• Study Type: observational
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality. Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies.

Conditions

Breast Cancer

Keywords

Breast cancer, SORCIN, Annexin A3

Outcome Measures

Primary Outcomes (1)

• Role of SORCIN in patients with breast cancer

  genetic expression of SORCIN new biomarker in breast cancer patients

  1 year

Secondary Outcomes (1)

• Role of annexin A3 biomarker in with breast cancer patients

  1 year

Study Arms (3)

Breast cancer patients

The present study will be carried on 50 breast cancer patients before surgery. The followings markers must be estimated: Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA).

Genetic: Sorcin gene expression; Other: Annexin A3 serum mesurement

Healthy controls

The present study will be carried on 15 age and sex matched controls. The followings markers must be estimated: Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA.

Genetic: Sorcin gene expression; Other: Annexin A3 serum mesurement

Benign breast diseases

The present study will be carried on 15 patients with benign breast diseases. The followings markers must be estimated: Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA.

Genetic: Sorcin gene expression; Other: Annexin A3 serum mesurement

Interventions

Sorcin gene expression GENETIC

Sorcin gene expression Will be measured by real time PCR

Benign breast diseases; Breast cancer patients; Healthy controls

Annexin A3 serum mesurement OTHER

serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)

Benign breast diseases; Breast cancer patients; Healthy controls

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

breast cancer patients

You may qualify if:

• breast cancer patients before surgery who are admitted to the South Egypt Cancer Institute, Surgery Department, Assiut University

You may not qualify if:

• Patients with malignancies elsewhere in the body.
• Patients with chronic cardiac diseases.
• Getting neoadjuvant chemotherapy.
• Renal disease.
• Neurodegenerative disease.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (4)

• Zeeneldin AA, Ramadan M, Elmashad N, Fakhr I, Diaa A, Mosaad E. Breast cancer laterality among Egyptian patients and its association with treatments and survival. J Egypt Natl Canc Inst. 2013 Dec;25(4):199-207. doi: 10.1016/j.jnci.2013.09.003. Epub 2013 Oct 25.

  PMID: 24207092 BACKGROUND

• Cubasch H, Joffe M, Ruff P, Dietz D, Rosenbaum E, Murugan N, Chih MT, Ayeni O, Dickens C, Crew K, Jacobson JS, Neugut A. Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PLoS One. 2017 Aug 10;12(8):e0182125. doi: 10.1371/journal.pone.0182125. eCollection 2017.

  PMID: 28797046 BACKGROUND

• Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules. 2014 Sep 5;19(9):13976-89. doi: 10.3390/molecules190913976.

  PMID: 25197934 BACKGROUND

• Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ, Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, Ju YT, Lee YJ, Hong SC. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer. Clin Breast Cancer. 2018 Aug;18(4):e713-e719. doi: 10.1016/j.clbc.2017.11.009. Epub 2017 Nov 21.

  PMID: 29217453 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

reham elmahdy

CONTACT

+201002714637; reham.elmahdy@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 8, 2018
• First Posted: July 26, 2018
• Study Start: January 20, 2019
• Primary Completion: August 1, 2019
• Study Completion: September 30, 2019
• Last Updated: January 9, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will not share